Sleep Architecture and Chemotherapy-Related Fatigue

Completed

Conditions studied: Fatigue, Sleep, Cancer

In brief

The purpose of this study is to identify specific chemotherapy-related changes in sleep stages/architecture that may relate to an increase in fatigue in individuals with cancer. The researchers hypothesize that the fatigue experienced by cancer patients receiving chemotherapy is in part due to changes in restorative sleeping during the non-rapid eye movement cycles of sleep (i.e., delta activity).

Key facts

Study ID: NCT00178204
Run by: University of Rochester
People needed: 26
Starts: 2004-11-01
Expected to finish: 2011-12-01
Last updated by the study team: 2014-12-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have a diagnosis of cancer and not have had chemotherapy during the prior three years
Be scheduled for chemotherapy that is expected to last at least 9 weeks but not more than 33 weeks without concurrent interferon treatment. Radiation therapy is allowed provided it is concluded within the 33 week time period
Have a stable sleep/wake schedule (no shift work) with a preferred sleep phase between 10:00 PM and 9:00 AM
Be 18 years of age or older
Give informed consent
If on beta blockers or being treated for depression or a thyroid disorder, the medication has been stable for 3 months

You may not qualify if…

On a short term basis (less than 3 months), taking any prescription medication for the control of anxiety, sleep, depression, or fatigue OR taking any over-the-counter medications known to affect sleep
Diagnosed with post-traumatic stress disorder (PTSD) or have a substance abuse disorder or psychotic disorder (currently or by history)

Where it is running

University of Rochester James P. Wilmot Cancer Center — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.